-
Focus on Life Sciences and Tech Companies and Their VC Investors
Danielle advises high-growth life sciences and technology companies, as well as their investors, on a variety of corporate matters, including formation, financing, secondary liquidity, M&A, recapitalization, and other transactions.
-
A Leader in the Venture Community
Danielle is an active member of the National Venture Capital Association’s General Counsel Advisory Board and a regular speaker on emerging company and venture capital topics.
Danielle Naftulin is a partner in the Palo Alto office of Wilson Sonsini with over 25 years of experience advising emerging companies and venture capital investors on a broad range of corporate transactions. Her practice focuses on the representation of high-growth life sciences and technology companies and their investors in formation and financing matters, as well as mergers and acquisitions, recapitalizations, spinouts, and general corporate matters. She has also represented clients in connection with initial public offerings and other public financing and strategic transactions.
Prior to joining the firm, Danielle was a partner in the business department at Cooley LLP in Palo Alto. She is an active member of the National Venture Capital Association’s General Counsel Advisory Board and a regular speaker on emerging companies and venture capital for Practising Law Institute, various law schools, and other organizations.
Danielle Naftulin is a partner in the Palo Alto office of Wilson Sonsini with over 25 years of experience advising emerging companies and venture capital investors on a broad range of corporate transactions. Her practice focuses on the representation of high-growth life sciences and technology companies and their investors in formation and financing matters, as well as mergers and acquisitions, recapitalizations, spinouts, and general corporate matters. She has also represented clients in connection with initial public offerings and other public financing and strategic transactions.
Prior to joining the firm, Danielle was a partner in the business department at Cooley LLP in Palo Alto. She is an active member of the National Venture Capital Association’s General Counsel Advisory Board and a regular speaker on emerging companies and venture capital for Practising Law Institute, various law schools, and other organizations.
- J.D., UCLA School of Law, 2000
- A.B., University of Michigan, Ann Arbor, 1997With Honors
- Member, General Counsel Advisory Board, National Venture Capital Association
- Recognized in the California Venture Capital category in the 2023-2026 editions of Chambers USA: America’s Leading Lawyers for Business
- Selected for inclusion in Lawdragon: 500 Leading Dealmakers in America, 2021, 2022, 2024, 2025, and 2026
- Honored by YWCA of Silicon Valley as part of its Tribute to Women in Industry
- Named in Northern California Super Lawyers’ “Rising Stars” list
- State Bar of California
- J.D., UCLA School of Law, 2000
- A.B., University of Michigan, Ann Arbor, 1997With Honors
- Member, General Counsel Advisory Board, National Venture Capital Association
- Recognized in the California Venture Capital category in the 2023-2026 editions of Chambers USA: America’s Leading Lawyers for Business
- Selected for inclusion in Lawdragon: 500 Leading Dealmakers in America, 2021, 2022, 2024, 2025, and 2026
- Honored by YWCA of Silicon Valley as part of its Tribute to Women in Industry
- Named in Northern California Super Lawyers’ “Rising Stars” list
- State Bar of California
Select Representations
Representative Investor-Side Deals
- Represented ARCH in connection with investments in Xaira* and others
- Represented G2VP in connection with investments in AssetWatch (formerly known as Nikola Labs)*, LightGuide Systems*, Locus Robotics*, Lumafield*, SmarterX*, and Waabi
- Represented GIC Special Investments in connection with investments in Amplitude*, Brex, Databricks*, Nubank*, Razorpay*, and Stack Exchange*
- Represented Norwest Venture Partners in connection with investments in Abodu*, Anomalo*, Diagrid*, Diana Health*, Fabric*, Harness*, Homeward*, Kustomer, ICON*, Lavender*, Nanopath*, Nectero Medical*, Noyo, Praxis Labs*, Session AI*, ShiraTronics*, Tempo*, Third Wave Automation*, and Uptycs*
- Represented Redmile Group in connection with investments in Impulse Dynamics*, Orbital Therapeutics*, and Saluda Medical
- Represented Sonder Capital in connection with investments in Avail Medsystems* and Neptune Medical*, and the associated spinout of Jupiter Endovascular*
- Represented Westbound Equity Fund in connection with investments in Conduit Tech*, Esusu, LaborUp*, Mon Ami*, and Snoots
- Handled significant deal work for ARCH Venture Partners*, Battery Ventures*, and DCM*, among others
Representative Company-Side Deals
- Represented Proxima in its $80 million Seed financing
- Represented Addition Therapeutics in multiple financings
- Represented AssetWatch in its $75 million Series C financing
- Represented Inceptive Nucleics in its $20 million Series Seed financing and $100 million Series A financing*
- Represented InkSpace Imaging in its $11 million Series A financing*
- Represented Lisa Health in its $2.5 million Seed Series financing*
- Represented Novoloop in its $11 million Series A financing and $21 million Series A extension*
- Represented OutcomesAI in its $10 million Seed financing
- Represented Protillion Biosciences in its $18 million Series A financing*
- Represented Quizizz in its $12.5 million Series A financing and $14 million Series B financing*
- Represented Slingshot Biosciences in its $23 million Series A financing and $11 million Series A-3 financing*
- Represented Visby Medical in its $135 million Series E financing*
- Represented Vivace Therapeutics in its $35 million Series D financing*
- Represented Vontive in its $25 million Series B financing*
* Denotes work performed at another firm prior to joining Wilson Sonsini in 2025
Select Representations
Representative Investor-Side Deals
- Represented ARCH in connection with investments in Xaira* and others
- Represented G2VP in connection with investments in AssetWatch (formerly known as Nikola Labs)*, LightGuide Systems*, Locus Robotics*, Lumafield*, SmarterX*, and Waabi
- Represented GIC Special Investments in connection with investments in Amplitude*, Brex, Databricks*, Nubank*, Razorpay*, and Stack Exchange*
- Represented Norwest Venture Partners in connection with investments in Abodu*, Anomalo*, Diagrid*, Diana Health*, Fabric*, Harness*, Homeward*, Kustomer, ICON*, Lavender*, Nanopath*, Nectero Medical*, Noyo, Praxis Labs*, Session AI*, ShiraTronics*, Tempo*, Third Wave Automation*, and Uptycs*
- Represented Redmile Group in connection with investments in Impulse Dynamics*, Orbital Therapeutics*, and Saluda Medical
- Represented Sonder Capital in connection with investments in Avail Medsystems* and Neptune Medical*, and the associated spinout of Jupiter Endovascular*
- Represented Westbound Equity Fund in connection with investments in Conduit Tech*, Esusu, LaborUp*, Mon Ami*, and Snoots
- Handled significant deal work for ARCH Venture Partners*, Battery Ventures*, and DCM*, among others
Representative Company-Side Deals
- Represented Proxima in its $80 million Seed financing
- Represented Addition Therapeutics in multiple financings
- Represented AssetWatch in its $75 million Series C financing
- Represented Inceptive Nucleics in its $20 million Series Seed financing and $100 million Series A financing*
- Represented InkSpace Imaging in its $11 million Series A financing*
- Represented Lisa Health in its $2.5 million Seed Series financing*
- Represented Novoloop in its $11 million Series A financing and $21 million Series A extension*
- Represented OutcomesAI in its $10 million Seed financing
- Represented Protillion Biosciences in its $18 million Series A financing*
- Represented Quizizz in its $12.5 million Series A financing and $14 million Series B financing*
- Represented Slingshot Biosciences in its $23 million Series A financing and $11 million Series A-3 financing*
- Represented Visby Medical in its $135 million Series E financing*
- Represented Vivace Therapeutics in its $35 million Series D financing*
- Represented Vontive in its $25 million Series B financing*
* Denotes work performed at another firm prior to joining Wilson Sonsini in 2025
- Privacy Policy
- Terms of Use
- Accessibility